CLDN18.2 CAR iNKT Cell Preclinical Data Update
Filed with ASX · · 5 pages · English
Summary by 6ix AI
The findings indicate that the armoured CAR-iNKT cells maintain their potency even after multiple challenges with cancer cells, highlighting their potential for treating difficult solid tumors. This announcement marks a significant milestone for Arovella as it expands its pipeline targeting challenging cancer types.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Half Year Report and Appendix 4D
- ALA's ind for ALA-101 accepted by the U.S.FDA
- Quarterly Activities/Appendix 4C Cash Flow Report
- Arovella Therapeutics appoints former CSL CSO Dr Andrew Nash as Non-executive Director
- Positive FDA Type D Meeting Outcome
Later from Arovella Therapeutics
- Board Refresh and CEO Resignation
- Arovella Appoints Acting CEO
- Clinical manufacturing batch released, first site activated
- The path to first patient dosing
- Second Clinical Batch Released for Immediate Patient Use
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics